Peptides for Men's Fat Loss: Targeting Visceral Fat and Body Composition

Fat loss peptides occupy a unique niche in the body composition toolkit. They're not stimulants, they don't cause muscle loss, and the best-studied options work specifically on visceral fat—the metabolically dangerous fat that accumulates in the abdomen. For men, this is particularly relevant: visceral fat accumulation accelerates with age, correlates directly with testosterone decline, and drives inflammation, insulin resistance, and cardiovascular risk.

This guide covers the most evidence-backed fat loss peptides for men, their mechanisms, realistic outcomes, and practical protocols.

Why Men Accumulate Visceral Fat Differently

Visceral fat—fat stored around the organs in the abdominal cavity—is the metabolically active, dangerous fat. Unlike subcutaneous fat, visceral fat:

• Secretes inflammatory cytokines (IL-6, TNF-alpha, resistin)
• Releases free fatty acids directly into the portal circulation, driving liver inflammation and insulin resistance
• Expresses aromatase enzymes that convert testosterone to estrogen
• Creates a hormonal environment (high estrogen, high cortisol, lower testosterone) that encourages more fat storage

In men over 35, declining testosterone accelerates visceral fat accumulation, which in turn lowers testosterone further—a vicious cycle. Breaking this cycle requires addressing fat loss at the hormonal and metabolic level, not just through calorie restriction.

Tesamorelin: The Visceral Fat Specialist

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is FDA-approved as Egrifta for HIV-associated lipodystrophy—a condition characterized by excess visceral fat accumulation. This clinical approval means we have rigorous human trial data on its fat-loss effects, which is unusual for peptides in this space.

Mechanism: Tesamorelin stimulates pulsatile GH secretion from the pituitary, which raises IGF-1 and drives lipolysis (fat breakdown) in visceral adipocytes. Unlike direct GH, tesamorelin preserves the natural feedback loop.

Clinical evidence:

• Phase III trials showed tesamorelin reduced visceral fat area by 18–20% over 26 weeks in HIV patients
• Waist circumference decreased by 3.6 cm on average
• The reduction was specific to visceral fat—subcutaneous fat was less affected
• IGF-1 levels increased appropriately, with no adverse effects on glucose or insulin resistance at therapeutic doses
• Benefits reversed within 12 weeks of stopping treatment

What this means for men without HIV lipodystrophy: The mechanism is identical. Men with excess visceral fat, particularly those with declining GH from somatopause, are pharmacologically similar to the populations studied. Many integrative physicians prescribe tesamorelin off-label for this reason.

Protocol:

• Clinical dose: 2 mg subcutaneously daily in the evening
• Off-label use often at 1–2 mg daily
• Cycle: 20–26 weeks, then reassess; some men run it longer under monitoring
• Monitor: IGF-1 (target 200–350 ng/mL), fasting glucose, HbA1c

AOD-9604: Fat-Specific GH Fragment

AOD-9604 is a modified fragment of the human growth hormone molecule—specifically the C-terminal portion (amino acids 177–191). This fragment retains GH's fat-metabolizing activity while lacking GH's anabolic (muscle and growth-stimulating) properties.

Why this matters: Full GH or GH secretagogues raise IGF-1, which has anabolic effects on multiple tissues. This isn't always desired—particularly if someone is concerned about IGF-1's potential effects on cancer risk or is not trying to build significant muscle. AOD-9604 targets fat metabolism more selectively.

Mechanisms:

• Stimulates lipolysis in adipocytes (fat cell breakdown)
• Inhibits lipogenesis (new fat creation)
• Does not raise IGF-1 levels
• Does not affect glucose or insulin in clinical studies at approved doses
• Was shown to have anabolic effects on cartilage in some studies (unexpected beneficial finding)

Clinical data: Phase II and III trials in obese individuals showed dose-dependent reductions in body weight—most pronounced at 1 mg/day. Phase III trials did not achieve statistical significance for the primary endpoint (total body weight loss) partly due to trial design issues, but consistently showed fat loss trends. The compound was given GRAS (Generally Recognized as Safe) status by the FDA for use as a food ingredient.

Protocol:

• Research dose: 250–300 mcg subcutaneously daily, preferably fasted (morning)
• Oral versions have poor bioavailability; subcutaneous is preferred for meaningful effect
• Cycle: 12–16 weeks; can be run longer since IGF-1 effects are absent
• Pairs well with CJC-1295/ipamorelin (different mechanisms, potentially additive)

CJC-1295 and Ipamorelin: Indirect Fat Loss Through GH Optimization

While CJC-1295/ipamorelin is discussed primarily in muscle-building contexts, its fat-loss effects in men are real and well-mechanized. This combination raises GH and IGF-1, which:

• Increases resting metabolic rate
• Shifts fuel utilization toward fat oxidation
• Reduces visceral fat over 6–12 months
• Improves insulin sensitivity (long-term)
• Preserves and builds lean mass simultaneously (improving body composition more than weight loss alone)

Fat loss vs. body recomposition: The key advantage over traditional fat loss peptides is simultaneous muscle preservation or gain. Men on CJC/ipamorelin typically experience true body recomposition—fat going down while muscle goes up—which is difficult to achieve through caloric restriction alone.

Realistic fat loss: 3–5% body fat reduction over 6 months of consistent use, combined with training and appropriate nutrition.

Protocol:

• CJC-1295 with DAC: 2 mg subcutaneously weekly
• Ipamorelin: 200–300 mcg subcutaneously 2–3 times daily (pre-sleep is most important)
• Best results when combined with resistance training and mild caloric deficit (200–300 cal below maintenance)

MOTS-c: Mitochondrial Fat Burning

MOTS-c is a peptide encoded in the mitochondrial genome—one of a class of mitochondrial-derived peptides (MDPs). It was identified relatively recently (2015) but has attracted significant research interest for its metabolic effects.

Mechanism: MOTS-c activates AMPK (AMP-activated protein kinase)—the cell's energy sensor and a master regulator of fat oxidation. AMPK activation mimics the metabolic effects of exercise at the cellular level:

• Increases glucose uptake
• Promotes fatty acid oxidation
• Reduces fat synthesis
• Improves insulin sensitivity
• Enhances mitochondrial function

Research findings: A landmark 2015 study in Cell Metabolism showed MOTS-c administration in mice reduced obesity and improved insulin sensitivity on a high-fat diet. More recent research showed MOTS-c improves muscle glucose uptake and physical endurance—effects that compound favorably with training for fat loss.

Practical notes:

• Research doses: 5–10 mg subcutaneously per week (often 2.5–5 mg twice weekly)
• Relatively new peptide—human data is limited but mechanisms are strong
• Best used as part of a comprehensive stack rather than as a standalone

Stacking Strategy: The Men's Fat Loss Peptide Protocol

For most men, stacking peptides with complementary mechanisms produces better results than any single agent:

Basic stack (most men):

• CJC-1295 with DAC: 2 mg weekly
• Ipamorelin: 200 mcg pre-sleep daily

Advanced stack for significant visceral fat:

• Tesamorelin: 1–2 mg daily (replaces CJC/ipamorelin during this cycle)
• AOD-9604: 250 mcg daily fasted morning
• BPC-157: 250 mcg daily (reduces inflammation from rapid fat loss, supports gut health)

Metabolic support:

• MOTS-c: 5 mg twice weekly (can run alongside either stack)

Nutrition Principles That Maximize Peptide Fat Loss

Peptides amplify the body's fat-burning signals, but they work best alongside the right metabolic conditions:

Fasting windows: Administering GH peptides in a fasted state produces greater GH release (insulin inhibits GH secretion). A 4–6 hour fast before morning and evening doses is optimal.

Protein adequacy: 0.7–1g per pound of body weight prevents muscle loss during fat loss phases and maximizes metabolic rate.

Resistance training: 3–4 sessions per week of compound training increases insulin sensitivity, drives GH pulse amplitude, and preserves lean mass during fat loss.

Sleep: GH is predominantly secreted during deep sleep. Inadequate sleep blunts GH response to secretagogue peptides by 30–50%. Prioritize 7–8 hours.

For a broader look at how fat loss peptides fit into men's overall optimization, see our guides on peptides for men's anti-aging and peptide protocols for men over 40.

Frequently Asked Questions

Q: Will fat loss peptides work without diet and exercise changes? Tesamorelin showed fat loss in clinical trials even in participants not making significant lifestyle changes—but the effect was modest (~18% visceral fat reduction). Men who combine peptides with appropriate nutrition and training see 2–3x better outcomes.

Q: How does tesamorelin compare to semaglutide (Ozempic) for fat loss? These work through entirely different mechanisms. Semaglutide reduces appetite and slows gastric emptying, producing significant total body weight loss but also significant lean mass loss. Tesamorelin works through GH, specifically reducing visceral fat while preserving or improving lean mass. They can potentially be complementary if a man has both significant obesity and significant visceral adiposity, though this requires physician oversight.

Q: Can I use fat loss peptides while in a caloric surplus (bulk)? Yes. During a muscle-building phase, CJC-1295/ipamorelin simultaneously supports muscle gain and blunts fat accumulation. AOD-9604 can similarly reduce the fat gain that typically accompanies a caloric surplus. Tesamorelin is generally reserved for fat-loss phases.

Q: Do peptides cause fat to come back when you stop? Tesamorelin's clinical data showed visceral fat returned to baseline within 12 weeks of stopping. This is not unique to peptides—any intervention that works through hormonal signaling will have reversible effects. The goal is to use peptides to reach a favorable body composition, then maintain it through lifestyle.

Q: Is AOD-9604 safe for men with pre-diabetes or insulin resistance? AOD-9604 notably does not raise IGF-1 and has shown no adverse effects on glucose or insulin in trials. It may be preferable to full GH secretagogues for men with metabolic concerns, though monitoring glucose quarterly is still advisable.